These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 19718485)
1. PPACK-Desmodus rotundus salivary plasminogen activator (cDSPAalpha1) prevents the passage of tissue-type plasminogen activator (rt-PA) across the blood-brain barrier and neurotoxicity. Roussel BD; Hommet Y; Macrez R; Schulz T; Petersen KU; Berezowski V; Cecchelli R; Ali C; Vivien D Thromb Haemost; 2009 Sep; 102(3):606-8. PubMed ID: 19718485 [No Abstract] [Full Text] [Related]
2. Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects. López-Atalaya JP; Roussel BD; Ali C; Maubert E; Petersen KU; Berezowski V; Cecchelli R; Orset C; Vivien D Stroke; 2007 Mar; 38(3):1036-43. PubMed ID: 17325305 [TBL] [Abstract][Full Text] [Related]
3. Fibrin selectivity of the isolated protease domains of tissue-type and vampire bat salivary gland plasminogen activators. Toschi L; Bringmann P; Petri T; Donner P; Schleuning WD Eur J Biochem; 1998 Feb; 252(1):108-12. PubMed ID: 9523718 [TBL] [Abstract][Full Text] [Related]
4. t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions. Freeman R; Niego B; Croucher DR; Pedersen LO; Medcalf RL Brain Res; 2014 May; 1565():63-73. PubMed ID: 24675027 [TBL] [Abstract][Full Text] [Related]
5. Optimized gene synthesis, expression and purification of active salivary plasminogen activator alpha2 (DSPAalpha2) of Desmodus rotundus in Pichia pastoris. Wei Z; Wang Y; Li G; Li X; Liu D Protein Expr Purif; 2008 Jan; 57(1):27-33. PubMed ID: 17950617 [TBL] [Abstract][Full Text] [Related]
6. HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator. Roussel BD; Mysiorek C; Rouhiainen A; Jullienne A; Parcq J; Hommet Y; Culot M; Berezowski V; Cecchelli R; Rauvala H; Vivien D; Ali C J Cell Sci; 2011 Jun; 124(Pt 12):2070-6. PubMed ID: 21610098 [TBL] [Abstract][Full Text] [Related]
7. rt-PA causes a dose-dependent increase in the extravasation of cellular and non-cellular blood elements after focal cerebral ischemia. Burggraf D; Martens HK; Dichgans M; Hamann GF Brain Res; 2007 Aug; 1164():55-62. PubMed ID: 17644075 [TBL] [Abstract][Full Text] [Related]
17. Tissue plasminogen activator use in a patient with acute ischemic stroke coexisting with meningioma. Hsieh HC; Chen CH Clin Neurol Neurosurg; 2009 Jul; 111(6):562-3. PubMed ID: 19200644 [No Abstract] [Full Text] [Related]
18. Increasing number of stroke specialists should contribute to utilization of IV rt-PA: results of questionnaires from 1,466 hospitals in Japan. Iguchi Y; Kimura K; Shibazaki K; Iwanaga T J Neurol Sci; 2009 Apr; 279(1-2):66-9. PubMed ID: 19185882 [TBL] [Abstract][Full Text] [Related]
19. [Current developments in fibrinolytic therapy]. Rijken DC Ned Tijdschr Geneeskd; 1985 Sep; 129(37):1768-72. PubMed ID: 3934567 [No Abstract] [Full Text] [Related]
20. The effect of anticonvulsant drugs on the fibrinolytic activity of tissue plasminogen activator. Zemke D; Farooq MU; Gupta R; Kassab M; Reeves M; Majid A Cerebrovasc Dis; 2008; 25(1-2):107-10. PubMed ID: 18057880 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]